Mostrar el registro sencillo del documento

dc.creatorZheng, Meijuan
dc.creatorGao, Yong
dc.creatorLiu, Siyu
dc.creatorSun, Dandan
dc.creatorYang, Fan
dc.creatorZong, Lu
dc.creatorZhang, Min
dc.creatorTian, Zhigang
dc.creatorXu, Yuanhong
dc.creatorSun, Haoyu
dc.date.accessioned2020-10-14T14:16:21Z
dc.date.available2020-10-14T14:16:21Z
dc.date.created2020
dc.identifier.issn1672-7681spa
dc.identifier.otherhttps://doi.org/10.1038/s41423-020-00551-1spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/14450
dc.description.abstractThe ongoing spread of coronavirus disease 2019 (COVID-19) constitutes an international concern on an unprecedented scale. To date, over 23 million people have been diagnosed with COVID19 worldwide, and this disease has caused more than 800,000 deaths. Hyperinflammation elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported to contribute to illness severity and death.1,2 Humoral immune responses play important roles in therapy and prophylaxis for SARS-CoV-2 infection. Since the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein binds to angiotensinconverting enzyme 2 to trigger virion endocytosis, antibodies against this domain may be able to neutralize SARS-CoV-2 and possibly provide protective immunity in COVID-19 patients.3 Clinical trials investigating the administration of convalescent plasma and the interleukin (IL)-6 antagonist tocilizumab to treat COVID-19 patients are currently underway,4 but the overly robust expansion of antibody-secreting cells (ASCs) could play a major role in the pathogenicity of SARS-CoV-2 in COVID-19 patients.5 Thus, a detailed characterization of the associations between humoral immune responses and inflammatory factors could result in a better understanding of SARS-CoV-2-host interactions in COVID-19 patients.spa
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCellular & Molecular Immunologyspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSerum inflammatory factorsspa
dc.subjectSpecific antibodiesspa
dc.subjectCoronavirus diseasespa
dc.subjectPatientsspa
dc.titleSerum inflammatory factors are positively correlated with the production of specific antibodies in coronavirus disease 2019 patientsspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1038/s41423-020-00551-1spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Archivos en el documento

ArchivosTamañoFormatoVer

No hay archivos asociados a este documento.

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento